Clinical trials: Biliary Cancers
Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
BTC-Ag-T (ACH-AgT001) is an autologous experimental T-cell therapy designed for advanced biliary tract cancer. This is an open-label, single-arm Phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of…
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Perihilar
- Trial name
- NCT07614061
- Testing
- BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Choledochal Cyst
Clinical Features and Prognosis of Asymptomatic Biliary Dilatation
This study is a multicenter, ambidirectional cohort study aiming to consecutively recruit asymptomatic biliary dilation patients incidentally discovered by imaging from 25 medical centers across China.
- Trial name
- NCT07028164
- Where
- China
- Volunteers
- 1,008 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Biliary Tract Cancer (BTC)
Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer
After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen
- Trial name
- PILOT-BTC (NCT07159204)
- Testing
- Paclitaxel polymer micelle immunocombination
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Biliary Tract Cancer, Cholangiocarcinoma
Biomarker Discovery in Patients With Advanced Biliary Tract Cancer
Biliary tract cancer is a rare gastrointestinal malignant neoplasm and includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancer.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT04871321
- Testing
- nab-paclitaxel plus gemcitabine-cisplatin
- Where
- South Korea
- Volunteers
- 119 people
- Sponsor
- CHA University
Biliary Tract Cancer (BTC), Surgery
Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases
This is a multicenter, open-label, single-arm, prospective phase II clinical study. Eligible patients with lymph node-positive biliary tract cancer will undergo primary tumor resection with selective lymph node dissection.
- Conditions
- Biliary Tract Cancer (BTC), Surgery, Radiotherapy
- Trial name
- NCT07893392
- Testing
- Primary Tumor Resection and Selective Lymph Node Dissection, Postoperative Radiotherapy, Capecitabine or S-1
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma, Cholangiocarcinoma
Hepatobiliary Tumors Tissue Samples Acquisition
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis…
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Gallbladder Cancer, Biliary Tract Cancer
- Trial name
- NCT04445532
- Testing
- Gene expression analysis, Genomic analysis, Protein expression analysis
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Biliary Tract Cancer
HAIC Rechallenge in Biliary Tract Cancer and Colorectal Cancer Liver Metastases: Efficacy and Safety in Patients Resistant to Previous Systemic Chemotherapy
Plain Language Summary This study uses hepatic arterial infusion chemotherapy (HAIC) rechallenge for patients with biliary tract cancer or colorectal cancer liver metastases whose disease has progressed after previous systemic…
- Trial name
- NCT07830147
- Testing
- Hepatic Arterial Infusion Chemotherapy (HAIC) Rechallenge
- Where
- China
- Volunteers
- 72 people
- Sponsor
- West China Hospital
Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
This study evaluates the change of quality of life, treatment decision and utilization of health care depending on the use of palliative care in advanced cancer patients by a prospective cohort study.
- Conditions
- Stage IV Breast Cancer, Stage IV Pancreatic Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer
- Trial name
- NCT03222258
- Testing
- Early palliative care, Routine hospice care
- Where
- 15 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma, Biliary Tract Cancer
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Although immune checkpoint inhibitors including nivolumab and pembrolizumab are now available for the management of hepatobiliary cancers in Korea, there is a lack of data for the efficacy and safety of these agents in the…
- Trial name
- NCT03695952
- Testing
- Nivolumab or pembrolizumab
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Unresectable Biliary Tract Cancer
Salvage mFOLFOX in BTC After Failure of Gemcitabine
The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.
- Trial name
- NCT01127555
- Testing
- 5-fluorouracil, leucovorin, oxaliplatin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chung-Ang University
Pancreatic Cancer
Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy
The purpose of this study is to demonstrate non-inferiority of Fully Covered biliary SEMS to Uncovered biliary SEMS in biliary drainage for the pre-operative management of biliary obstructive symptoms caused by pancreatic cancer…
- Trial name
- NCT02238847
- Testing
- WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 119 people
- Sponsor
- Boston Scientific Corporation
Biliary Tract Cancer
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
This is a phase II, multicenter, open-label study with a safety run-in to evaluate the safety and efficacy of GEN-001 in combination with pembrolizumab or in combination with pembrolizumab and mFOLFOX for patients with advanced…
- Trial name
- NCT05998447
- Testing
- GEN-001, Pembrolizumab, mFOLFOX
- Where
- 6 sites in South Korea
- Volunteers
- 10 people
- Sponsor
- Genome & Company
Biliary Tract Cancer (BTC)
A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
This is a randomized, two-cohort, multicenter Phase II clinical study. To evaluate the efficacy and safety of liposomal irinotecan II and 5-FU/LV combined with or without renvastinib in the treatment of patients with advanced…
- Trial name
- NCT07099794
- Testing
- Liposomal irinotecan+5-FU/LV+Lenvatinib, NALIRI
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00059865
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 41 sites in United States
- Volunteers
- 68 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Biliary Tract Carcinoma, Gallbladder Carcinoma
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
This is a phase II study (the second stage of testing a new drug or new drug combinations) to see how useful two different schedules of study drug selumetinib with cisplatin and gemcitabine are compared to cisplatin and…
- Trial name
- NCT02151084
- Testing
- Selumetinib, Cisplatin, Gemcitabine
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- University Health Network, Toronto
Distal Bile Duct Obstruction
Covered vs Uncovered Metal Stents for Palliative Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction
The purpose of this study is to compare the rate of long-term stent failure, defined as need for repeat biliary intervention following placement of C-SEMS vs U-SEMS for palliation of inoperable malignant distal bile duct…
- Trial name
- NCT01905384
- Testing
- Covered Self-expanding metal biliary stents (C-SEMS), Uncovered Self-expanding metal biliary stents (U-SEMS)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt University Medical Center
Cholangiocarcinoma Resectable
Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA
Biliary tract cancer is a highly aggressive and heterogeneous group of gastrointestinal cancers that arise from the intra- or extrahepatic bile ducts (CCA), or the gallbladder (GBC)(1-3).
- Trial name
- NEOLANGIO (NCT06569225)
- Testing
- Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma, Biliary Tract Cancer
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally…
- Trial name
- NCT05733598
- Testing
- RP2, Bevacizumab, Atezolizumab
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Replimune, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.